糖尿病治疗药物的药物经济学研究

摘要

Objective:Take different oral hypoglycemic drugs to compose different therapeutic schemes , and compare the differences a-mong these therapeutic schemes in terms of economics , efficacy and safety.Discuss the advantages of Xiaoke pill in pharmacoeconomic aspects.Methods:A total of 296 cases of patients with diabetes mellitus were randomly divided into four groups , and adopted four kinds of treatment.Observe the clinical efficacy and cost effectiveness of the four groups of patients .Results:The four therapeutic schemes had no significant difference in efficacy or safety .In the study of pharmaceutical economics , Metformin group had the lowest rate of C/E and total cost /HbA1c.Xiaoke pill group ranked second, followed by Glipizide group and Repaglinide group .Conclusion:Considering the efficacy, safety and economy aspects , metformin or Xiaoke pill can be used for initial therapy for type-2 diabetes.Combination of the two can also be used if necessary.Through effective management , it helps to save cost and improve the level of blood glucose control .%目的：采取不同口服降糖药，组成价格不等的治疗方案，比较方案的经济学、有效性和安全性的差异，探讨消渴丸在药物经济学方面的优势。方法：选取糖尿病患者296例，随机分为4组，采取4种治疗方案，观察4组患者的临床效果及成本效果。结果：在安全性和有效性方面，4种治疗方案没有统计学意义，在药物经济学研究上，二甲双胍的C/E和总花费/HbA1c比率最低，可以认为最为经济，消渴丸次之，再次为格列吡嗪和瑞格列奈。结论：从药物有效性、经济性和安全性方面综合考虑，2型糖尿病的起始降糖治疗用药可选择二甲双胍或消渴丸，必要时两药联合；通过有效的管理有助于节省成本，改善血糖控制水平。